Verastem Stock Today
| VSTM Stock | USD 6.41 0.18 2.89% |
PerformanceWeakest
| Odds Of DistressRisky
|
Verastem is selling at 6.41 as of the 30th of January 2026; that is 2.89 percent increase since the beginning of the trading day. The stock's lowest day price was 6.15. Verastem has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 1st of November 2025 and ending today, the 30th of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of January 2012 | Category Healthcare | Classification Health Care |
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts. Verastem operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 75.32 M outstanding shares of which 17.12 M shares are at this time shorted by private and institutional investors with about 8.15 trading days to cover. More on Verastem
Moving together with Verastem Stock
Moving against Verastem Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Verastem Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Daniel Paterson | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Verastem utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Verastem's leverage profile, showing how much of Verastem's resources are funded through borrowing.
| |||||
Verastem (VSTM) is traded on NASDAQ Exchange in USA and employs 78 people. Verastem is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 482.8 M. Verastem conducts business under Biotechnology sector and is part of Health Care industry. The entity has 75.32 M outstanding shares of which 17.12 M shares are at this time shorted by private and institutional investors with about 8.15 trading days to cover.
Verastem currently holds about 94.31 M in cash with (104.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5.
Check Verastem Probability Of Bankruptcy
Ownership AllocationVerastem shows a total of 75.32 Million outstanding shares. The majority of Verastem outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Verastem to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Verastem. Please pay attention to any change in the institutional holdings of Verastem as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Verastem Ownership Details
Verastem Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Vivo Capital, Llc | 2025-06-30 | 1.5 M | |
| Goldman Sachs Group Inc | 2025-06-30 | 1.5 M | |
| Stonepine Capital Management Llc | 2025-06-30 | 1.4 M | |
| Foresite Capital Management Vi Llc | 2025-06-30 | 1.3 M | |
| Geode Capital Management, Llc | 2025-06-30 | 1.2 M | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.1 M | |
| Polar Capital Holdings Plc | 2025-06-30 | 1000 K | |
| Logos Global Management Lp | 2025-06-30 | 1000 K | |
| Soleus Capital Management, L.p. | 2025-06-30 | 935.9 K | |
| Rtw Investments, Llc | 2025-06-30 | 4.3 M | |
| Balyasny Asset Management Llc | 2025-06-30 | 4.2 M |
Verastem Historical Income Statement
Verastem Stock Against Markets
Verastem Corporate Management
| Jonathan Pachter | Chief Officer | Profile | |
| Michael Crowther | Chief Officer | Profile | |
| Sean Flynn | Gen VP | Profile | |
| MD MSc | Head Strategy | Profile | |
| Robert Weinberg | CoFounder Board | Profile | |
| Daniel Calkins | Interim Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verastem. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Will Biotechnology sector continue expanding? Could Verastem diversify its offerings? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Verastem data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.28) | Revenue Per Share | Quarterly Revenue Growth (0.79) | Return On Assets | Return On Equity |
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Verastem's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.